Gene Editing and IP

Gene Editing and IP

What is Gene editing?

Genome editing is a technique for changing a cell’s or an organism’s DNA in a precise way. With the help of targeted nucleases, it is possible to easily alter practically any genomic sequence. This has opened up intriguing new opportunities for human gene therapy, creating isogenic cell lines and animal models for the study of human disease. WHO International Clinical Trials Registry Platform (ICTRP) collects data about the clinical trials using human genome editing technologies and maintains the data in a central database, The Human Genome Editing (HGE) Registry.

Gene editing & IP

Since 2010, we witnessed the rise of highly adaptable genome-editing technologies and it has hastened scientific advances and discoveries in fields such as synthetic biology, human gene therapy, disease modelling, drug development, neurology, and agricultural sciences.

The following few charts depicts

a) Timeline of patent applications/granted patents in gene editing

b) count of patents/publications jurisdictions wise

c) top assignees in the field of gene editing

d) key classifications (IPC/CPC) under which the gene editing patents/publications are filed.

Timeline of patent applications/granted patents in gene editing

No Data Found

Count of patents/publications jurisdictions wise

count of patents publications jurisdictions wise

Top assignees in the field of gene editing

Top assignees in the field of gene editing

Key classifications (IPC/CPC) under which the gene editing patents/publications are filed

key classifications

Among the various gene editing technologies, three of them have facilitated a genome-editing revolution. They are clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9), transcription activator-like effector nucleases (TALENs), and zinc-finger nucleases (ZFNs). Prior to the development of designed (targeted) nucleases, it was time-consuming, expensive, and frequently restricted to laboratories with specialised knowledge to genetically edit mammalian cell lines. But now with the development of affordable and user-friendly gene-editing technologies, it is possible to create unique cell lines with almost any genomic change in only a few short weeks. A quick IP glance on 3 ground-breaking gene editing tools is shown below in charts.

IP filing trends in CRISPR

Patent families by first priority year

Patent Families

Top patent owners

Top patent owners

IP filing trends in Zinc-Finger Nucleases (ZFNs)

Patent families by first priority year

Top patent owners

Zinc-Finger Nucleases top assignees

IP filing trends in Transcription Activator-Like Effector Nucleases (TALENs)

Patent families by first priority year

TALEN Filings

Top patent owners

TALEN assignees

Recent trends in Gene editing

Researchers have been able to correct mutations that lead to hereditary disease in an organism’s DNA using the gene editing technology CRISPR/Cas9. The CRISPR/Cas9 technique, however, can potentially lead to unintentional DNA alterations that could have adverse repercussions.

Recently, a new genome editing method that is equally efficient as CRISPR/Cas9 and dramatically lowers these unwanted mutations has just been created by Japanese researchers. An innovative method for editing the genome called NICER was created by researchers at Osaka University. It takes use of an enzyme that creates single-stranded “nicks” in DNA. In comparison to existing CRISPR/Cas9 editing, repair of these nicks is more effective and accurate. For the treatment of genetic disorders brought on by heterozygous mutations, this method represents a fresh strategy.

CRISPR genome editing

Base editing, a high-precision alternative to CRISPR genome editing, has achieved a significant milestone by making its US debut in a clinical experiment. The trial examines more intricate genomic alterations than have previously been carried out on humans. The trial’s organisers revealed on September 5, 2023 that the first patient had received treatment with immune cells that had four base-edited genes, enabling the cells to more effectively target and eradicate cancers.

How can MCRPL help?

MCRPL is a 20-year-old company that undertakes all kinds of searches involving all scientific, and technical information that exists. Our team consists of several experts holding Masters and Ph.D. degrees in different fields. We apply extensive resources and knowledge to work on several challenging and extremely complex searches.

We use the Human-plus-Machine approach (MCRANK) to ensure that our quality output is immaculate, with well-maintained and documented SOPs, and internal manuals for working on typical IP projects. We have many patent agents that give us an edge in performing complex searches.

© Molecular Connections Private Limited

For more information, contact

For more updates subscribe IP Tech Insider

Interested in Gene Editing and IP ? Reach out to us.